NCT06573567

Brief Summary

The goal of this clinical trial is to learn if bioimpedance-guided fluid management can help decrease hemodialysis complications. The main questions it aims to answer are: Does bioimpedance-guided fluid management decrease major cardiovascular events? Does bioimpedance-guided fluid management decrease other hemodialysis complications? Participants will: Take bioimpedance analysis once per month Adjust dry weight according to the analysis as possible in active group Blind the analysis results to the doctor and the patient in the control group

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Sep 2024

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 21, 2024

Completed
6 days until next milestone

First Posted

Study publicly available on registry

August 27, 2024

Completed
5 days until next milestone

Study Start

First participant enrolled

September 1, 2024

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 11, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 11, 2026

Completed
Last Updated

February 13, 2026

Status Verified

February 1, 2026

Enrollment Period

1.4 years

First QC Date

August 21, 2024

Last Update Submit

February 11, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Major adverse cardiovascular events

    A composite of myocardial infarction, stroke and all-cause mortality

    From first bioimpedance analysis done to 1 year later

Secondary Outcomes (5)

  • The number of hemodialysis sessions with intradialytic hypotension

    From first bioimpedance analysis done to 1 year later

  • The number of hemodialysis sessions with intradialytic cramps or postdialytic cramps

    From first bioimpedance analysis done to 1 year later

  • The number of hemodialysis sessions with pitting edema

    From first bioimpedance analysis done to 1 year later

  • The number of hemodialysis sessions with lung edema

    From first bioimpedance analysis done to 1 year later

  • The number of hemodialysis sessions with non-function of arteriovenous shunt

    From first bioimpedance analysis done to 1 year later

Study Arms (2)

Bioimpedance

EXPERIMENTAL

Use overhydration value obtained by bioimpedance analysis to guide fluid management; the measurements will be obtained once per month

Device: Bioimpedance

Control

PLACEBO COMPARATOR

Bioimpedance analysis done, but the results will be masked to the participants, care providers and outcome evaluators

Device: Control

Interventions

Experimental: use overhydration value obtained by bioimpedance analysis to guide fluid management; the measurements will be obtained once per month

Bioimpedance
ControlDEVICE

Placebo Comparator: the measurements will also be obtained once per month, but not revealed to the participants and the care providers

Control

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Has received hemodialysis \>= 3 months
  • Has at least 1 pair of intact same-side upper extremity and lower extremity

You may not qualify if:

  • Pregnant
  • With a cardiac pacemaker
  • With metallic implants that may interfere with measurements (cardiac stents acceptable)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cishan Hospital, MOHW, Taiwan

Kaohsiung City, 842, Taiwan

Location

Related Publications (6)

  • Liu L, Sun Y, Chen Y, Xu J, Yuan P, Shen Y, Lin S, Sun W, Ma Y, Ren J, Liu W, Lei J, Zuo L. The effect of BCM guided dry weight assessment on short-term survival in Chinese hemodialysis patients : Primary results of a randomized trial - BOdy COmposition MOnitor (BOCOMO) study. BMC Nephrol. 2020 Apr 15;21(1):135. doi: 10.1186/s12882-020-01793-x.

  • Onofriescu M, Mardare NG, Segall L, Voroneanu L, Cusai C, Hogas S, Ardeleanu S, Nistor I, Prisada OV, Sascau R, Covic A. Randomized trial of bioelectrical impedance analysis versus clinical criteria for guiding ultrafiltration in hemodialysis patients: effects on blood pressure, hydration status, and arterial stiffness. Int Urol Nephrol. 2012 Apr;44(2):583-91. doi: 10.1007/s11255-011-0022-y. Epub 2011 Jun 19.

  • Hur E, Usta M, Toz H, Asci G, Wabel P, Kahvecioglu S, Kayikcioglu M, Demirci MS, Ozkahya M, Duman S, Ok E. Effect of fluid management guided by bioimpedance spectroscopy on cardiovascular parameters in hemodialysis patients: a randomized controlled trial. Am J Kidney Dis. 2013 Jun;61(6):957-65. doi: 10.1053/j.ajkd.2012.12.017. Epub 2013 Feb 15.

  • Onofriescu M, Hogas S, Voroneanu L, Apetrii M, Nistor I, Kanbay M, Covic AC. Bioimpedance-guided fluid management in maintenance hemodialysis: a pilot randomized controlled trial. Am J Kidney Dis. 2014 Jul;64(1):111-8. doi: 10.1053/j.ajkd.2014.01.420. Epub 2014 Feb 28.

  • Huan-Sheng C, Yeong-Chang C, Ming-Hsing H, Fan-Lieh T, Chu-Cheng L, Tsai-Kun W, Hung-Ping C, Sze-Hung H, Hsien-Chang C, Chia-Chen L, Chun-Cheng H, Chun-Ting C, Hung-Hsiang L, Chun-Ju L, Paik-Seong L. Application of bioimpedance spectroscopy in Asian dialysis patients (ABISAD-III): a randomized controlled trial for clinical outcomes. Int Urol Nephrol. 2016 Nov;48(11):1897-1909. doi: 10.1007/s11255-016-1415-8. Epub 2016 Sep 12.

  • Patel HV, Annigeri RA, Kowdle PC, Rao BS, Seshadri R, Balasubramanian S, Vadamalai V. Bioimpedance Spectroscopy-Guided Ultrafiltration Normalizes Hydration and Reduces Intradialytic Adverse Events in Hemodialysis Patients. Indian J Nephrol. 2019 Jan-Feb;29(1):1-7. doi: 10.4103/ijn.IJN_150_18.

Study Officials

  • Han-Ming Kuo, Master

    Cishan Hospital, MOHW, Taiwan

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director, Division of Nephrology

Study Record Dates

First Submitted

August 21, 2024

First Posted

August 27, 2024

Study Start

September 1, 2024

Primary Completion

February 11, 2026

Study Completion

February 11, 2026

Last Updated

February 13, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will share

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Shared Documents
STUDY PROTOCOL, SAP
Time Frame
one year after the research published
Access Criteria
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Locations